spacer
home > ebr > winter 2002 > from genes to drugs
PUBLICATIONS
European Biopharmaceutical Review

From Genes to Drugs

One of the biggest obstacles in the development of cancer therapeutics is the sheer complexity of the problem. Cancer may result from a large number of genetic and molecular defects, or combination of these defects, giving rise to loss of cell cycle checkpoints and unregulated cell division. Even individual tumours may exhibit heterogeneous phenotypes at the cellular level. The inherent genetic instability of cancer cells may also add to the problem, enabling them to continue to change during treatment and effectively presenting a moving target.The majority of anti-cancer therapeutics currently in use were discovered due to their ability to kill fast-growing cancer cells. Unfortunately, these often cause severe side effects due to their impact on other fast-growing cells in the body. There is, therefore, a need to design drugs that target a specific pathogenic pathway and to base the design of the drug upon the structure of its protein target.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Bob Jackson, Executive Director of R&D at Cyclacel Dr Robert Jackson joined Cyclacel in January 2001. Prior to this he was Research and Development Director at Celltech Group plc and Executive Director, R&D and Chief Operating Officer at Chiroscience Group plc.
Before these appointments, Dr Jackson was Vice President of R&D at Agouron Pharmaceuticals and headed cancer research at DuPont Pharmaceuticals and Warner-Lambert Company. Dr Jackson has been instrumental in the discovery and development of several marketed drugs used to treat cancer, HIV and other serious diseases. He holds a BA from the University of Cambridge and a PhD from the University of London, Institute of Cancer Research.

spacer
Dr Bob Jackson
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Discussing developments on Highly Potent APIs with industry expert, Richard Arnett for the HPAPI USA conference 2019

Ahead of the 2019 HPAPI USA Conference taking place in Boston on 21st – 22nd October, SMi caught up with Richard Arnett, Manager, Industrial Hygiene, Pharmascience who is speaking on Day Two of the agenda. Richard shared his thoughts on how the industry has developed and briefly touched on what he will be discussing in October.
More info >>

White Papers

Why You Should Be Using Ultrasonic Cleaning

Natoli Engineering Company, Inc.

Clean punches and dies are essential to maintaining the integrity and efficiency of your tooling investment, as well as the quality of your product. Ultrasonic cleaning has long been considered the most effective, nondestructive way to clean tools – from medical instruments to tablet tooling. The Tableting Specification Manual (TSM) states, “An ultrasonic bath is ideal for cleaning tooling.” This high-tech cleaning process also saves time, reduces cost and is better for the environment.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement